Other ‘Seismic shift’ as obesity overtakes cancer for R&D returns PharmaphorumFor the first time in its 16-year history, Deloitte's annual report on pharma R D returns sees obesity replace cancer as the largest driver.Metabolic & GLP-1Read full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaphorum For the first time in its 16-year history, Deloitte’s annual report on pharma R D returns sees obesity replace cancer as the largest driver. Metabolic & GLP-1 Read full story Post navigation Previous: Latus Bio secures $97m in funding to boost gene therapy accessNext: Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara Related Stories Other Takeda and Weave Bio collaborate on AI-driven automation in drug development pharminent September 2, 2026 Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026